Relay Therapeutics/$RLAY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
$RLAY
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
259
ISIN
US75943R1023
Website
RLAY Metrics
BasicAdvanced
$566M
-
-$2.19
1.65
-
Price and volume
Market cap
$566M
Beta
1.65
52-week high
$9.77
52-week low
$1.78
Average daily volume
1.5M
Financial strength
Current ratio
19.963
Quick ratio
19.172
Long term debt to equity
5.718
Total debt to equity
6.54
Profitability
EBITDA (TTM)
-373.071
Gross margin (TTM)
-3,895.92%
Net profit margin (TTM)
-4,341.53%
Operating margin (TTM)
-4,927.05%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-28.82%
Return on equity (TTM)
-45.46%
Valuation
Price to revenue (TTM)
65.522
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-1.846
Free cash flow yield (TTM)
-54.18%
Free cash flow per share (TTM)
-178.81%
Growth
Revenue change (TTM)
-78.26%
Earnings per share change (TTM)
-16.98%
3-year revenue growth (CAGR)
45.44%
3-year earnings per share growth (CAGR)
-17.19%
What the Analysts think about RLAY
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
Bulls say / Bears say
Relay Therapeutics' lead product candidate, RLY-4008, has shown promising preliminary data in treating FGFR2 fusion and amplified tumors, indicating potential for significant market impact upon approval. (markets.businessinsider.com)
The company maintains a strong financial position with approximately $810.6 million in cash and equivalents as of Q3 2023, expected to fund operations into the second half of 2026, providing stability for ongoing and future projects. (globenewswire.com)
Analysts have expressed optimism, with Raymond James upgrading Relay Therapeutics to a 'Strong Buy' rating in April 2023, reflecting confidence in the company's growth prospects. (nasdaq.com)
Relay Therapeutics reported a net loss of $337.7 million in 2024, indicating ongoing financial challenges that may impact future operations. (finviz.com)
The company's revenue declined from $25.5 million in 2023 to $10 million in 2024, primarily due to reduced milestone payments, raising concerns about revenue sustainability. (finviz.com)
Leerink Partners lowered its price target for Relay Therapeutics from $19.00 to $18.00 in December 2024, suggesting tempered expectations for the stock's performance. (tickerreport.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RLAY Financial Performance
Revenues and expenses
RLAY Earnings Performance
Company profitability
RLAY News
AllArticlesVideos
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
GlobeNewsWire·3 weeks ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
GlobeNewsWire·1 month ago
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $566M as of June 30, 2025.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of June 30, 2025.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.